Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Cantor Fitzgerald
Deloitte
Boehringer Ingelheim
Cerilliant
Julphar
US Army
Accenture
McKinsey

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ABACAVIR SULFATE; LAMIVUDINE

« Back to Dashboard

Clinical Trials for Abacavir Sulfate; Lamivudine

Trial ID Title Status Sponsor Phase Summary
NCT00078247 Anti-HIV Drugs for Ugandan Patients With HIV and Tuberculosis Completed Makerere University Phase 3 This study is designed to determine whether 6 months of anti-HIV drugs given along with tuberculosis treatment will delay the onset of AIDS in HIV infected African patients.
NCT00078247 Anti-HIV Drugs for Ugandan Patients With HIV and Tuberculosis Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 3 This study is designed to determine whether 6 months of anti-HIV drugs given along with tuberculosis treatment will delay the onset of AIDS in HIV infected African patients.
NCT00084149 Safety of and Immune Response to Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in Adults With Acute HIV Infection Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 Cyclosporine A (CsA) is a common long-term treatment used to inhibit the immune response in transplant patients who receive donor organs. CsA may also help people with HIV. The purpose of this study is to determine the safety of and immune response to CsA when given with abacavir sulfate, lamivudine, and zidovudine (ABC/3TC/AZT) and lopinavir/ritonavir (LPV/r) to HIV infected adults in the early stages of infection. Study hypothesis: The combination of CsA and LPV/r given to acutely infected individuals will result in lower levels of proviral DNA and latent infectious virus at 48 weeks compared to acute infected individuals treated with LPV/r alone.
NCT00102206 A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 2 HIV infected children and adolescents who have taken many anti-HIV drugs may have limited treatment options and are at high risk for progressing to AIDS. The purpose of this study is to determine whether an anti-HIV treatment regimen of 2 protease inhibitors (PIs) and 2 nucleoside reverse transcriptase inhibitors (NRTIs) is more effective than a regimen of 4 NRTIs in treatment-experienced children and adolescents who have failed previous anti-HIV treatment.
NCT00102206 A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 HIV infected children and adolescents who have taken many anti-HIV drugs may have limited treatment options and are at high risk for progressing to AIDS. The purpose of this study is to determine whether an anti-HIV treatment regimen of 2 protease inhibitors (PIs) and 2 nucleoside reverse transcriptase inhibitors (NRTIs) is more effective than a regimen of 4 NRTIs in treatment-experienced children and adolescents who have failed previous anti-HIV treatment.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Abacavir Sulfate; Lamivudine

Condition Name

Condition Name for Abacavir Sulfate; Lamivudine
Intervention Trials
HIV Infections 5
HIV Infection 2
Tuberculosis 1
Infection, Human Immunodeficiency Virus 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Abacavir Sulfate; Lamivudine
Intervention Trials
HIV Infections 8
Acquired Immunodeficiency Syndrome 3
Infection 2
Communicable Diseases 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Abacavir Sulfate; Lamivudine

Trials by Country

Trials by Country for Abacavir Sulfate; Lamivudine
Location Trials
United States 48
Canada 5
Mexico 4
Puerto Rico 2
Netherlands 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Abacavir Sulfate; Lamivudine
Location Trials
New York 4
Illinois 3
North Carolina 3
New Jersey 2
District of Columbia 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Abacavir Sulfate; Lamivudine

Clinical Trial Phase

Clinical Trial Phase for Abacavir Sulfate; Lamivudine
Clinical Trial Phase Trials
Phase 4 2
Phase 3 3
Phase 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Abacavir Sulfate; Lamivudine
Clinical Trial Phase Trials
Completed 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Abacavir Sulfate; Lamivudine

Sponsor Name

Sponsor Name for Abacavir Sulfate; Lamivudine
Sponsor Trials
National Institute of Allergy and Infectious Diseases (NIAID) 5
GlaxoSmithKline 2
Makerere University 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Abacavir Sulfate; Lamivudine
Sponsor Trials
NIH 6
Industry 4
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
McKinsey
Covington
Cipla
Baxter
Julphar
Accenture
Mallinckrodt
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.